Engineers Gate Manager LP Buys 33,329 Shares of Bruker Corporation $BRKR

Key Points

• Engineers Gate Manager LP increased its Bruker stake by 141.8% in the second quarter, acquiring 33,329 shares and bringing its total holdings to 56,825 shares worth approximately $3.42 million. Institutional investors collectively own 79.52% of Bruker.
• Analysts have a mixed outlook, with a consensus “Hold” rating and an average price target of $57.00. Ratings include one Strong Buy, six Buys, five Holds and two Sells.
• Bruker reported quarterly EPS of $0.49, beating estimates of $0.38, while revenue rose 5.2% year over year to $838.5 million but fell short of expectations. The company also declared a quarterly dividend of $0.05 per share, equal to a 0.4% annualized yield.

Engineers Gate Manager LP lifted its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 141.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,825 shares of the medical research company's stock after acquiring an additional 33,329 shares during the quarter. Engineers Gate Manager LP's holdings in Bruker were worth $3,420,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Arizona State Retirement System grew its stake in Bruker by 0.6% in the second quarter. Arizona State Retirement System now owns 29,402 shares of the medical research company's stock worth $1,769,000 after purchasing an additional 188 shares in the last quarter. Allworth Financial LP raised its position in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Federated Hermes Inc. raised its position in Bruker by 6.7% during the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company's stock valued at $284,000 after purchasing an additional 380 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company's stock worth $41,000 after buying an additional 479 shares during the period. Finally, IFP Advisors Inc lifted its holdings in shares of Bruker by 88.6% in the 2nd quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company's stock worth $64,000 after buying an additional 498 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Wall Street Analyst Weigh In

BRKR has been the topic of several research reports. Wolfe Research initiated coverage on Bruker in a research note on Monday, June 1st. They set a "peer perform" rating on the stock. Zacks Research lowered shares of Bruker from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 2nd. TD Cowen reiterated a "hold" rating on shares of Bruker in a report on Wednesday, July 15th. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Bruker in a report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Bruker currently has a consensus rating of "Hold" and an average target price of $57.00.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $53.43 on Monday. Bruker Corporation has a 12-month low of $30.09 and a 12-month high of $65.30. The stock's fifty day simple moving average is $58.25 and its two-hundred day simple moving average is $49.32. The stock has a market capitalization of $8.14 billion, a PE ratio of -76.33, a price-to-earnings-growth ratio of 1.63 and a beta of 1.26. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a $0.05 dividend. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker's payout ratio is currently -28.57%.

Bruker Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.